bivalirudin is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Maia Pharmaceuticals, Inc.. The primary component is Bivalirudin.
Product ID | 70511-141_50aa9ddb-2b42-4c1f-958d-979e341446e5 |
NDC | 70511-141 |
Product Type | Human Prescription Drug |
Proprietary Name | bivalirudin |
Generic Name | Bivalirudin |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2019-08-08 |
Marketing Category | NDA / NDA |
Application Number | NDA211215 |
Labeler Name | MAIA Pharmaceuticals, Inc. |
Substance Name | BIVALIRUDIN |
Active Ingredient Strength | 250 mg/1 |
Pharm Classes | Anti-coagulant [EPC],Direct Thrombin Inhibitor [EPC],Thrombin Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2019-08-08 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA211215 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-08-08 |
Marketing Category | NDA |
Application Number | NDA211215 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-08-08 |
Ingredient | Strength |
---|---|
BIVALIRUDIN | 250 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
0409-8300 | Bivalirudin | BIVALIRUDIN |
0781-3158 | bivalirudin | bivalirudin |
0781-9158 | bivalirudin | bivalirudin |
16729-275 | Bivalirudin | Bivalirudin |
25021-405 | bivalirudin | bivalirudin |
52958-034 | Bivalirudin | Bivalirudin |
55111-652 | Bivalirudin | Bivalirudin |
55150-210 | BIVALIRUDIN | BIVALIRUDIN |
60505-6101 | Bivalirudin | bivalirudin |
63323-562 | Bivalirudin | Bivalirudin |
67457-256 | Bivalirudin | bivalirudin |
69097-601 | bivalirudin | bivalirudin |
70511-141 | bivalirudin | bivalirudin |
70860-402 | Bivalirudin | Bivalirudin |
72572-035 | bivalirudin | bivalirudin |
71288-427 | BIVALIRUDIN | BIVALIRUDIN |
0781-3447 | Angiomax | bivalirudin |
65293-001 | Angiomax | bivalirudin |